Turning Point Therapeutics, Inc. (TPTX) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
10628 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO, CA 92121 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 6/30/2022 MRQ | 12/31/2021 | 12/31/2020 | 12/31/2019 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments, including: | 980,706 | 1,121,875 | 406,048 | |||
| Cash and cash equivalents | 427,879 | 554,101 | 48,188 | |||
| Short-term investments | 553,703 | 568,407 | 360,963 | |||
| Other undisclosed cash, cash equivalents, and short-term investments | (876) | (633) | (3,103) | |||
| Other undisclosed current assets | 11,756 | 8,804 | 8,899 | |||
| Total current assets: | 992,462 | 1,130,679 | 414,947 | |||
| Noncurrent Assets | ||||||
| Operating lease, right-of-use asset | 5,158 | 3,357 | 4,493 | |||
| Property, plant and equipment | 3,822 | 2,604 | 2,689 | |||
| Other noncurrent assets | 2,021 | 73 | ||||
| Other undisclosed noncurrent assets | 73 | |||||
| Total noncurrent assets: | 11,001 | 6,034 | 7,255 | |||
| TOTAL ASSETS: | 1,003,463 | 1,136,713 | 422,202 | |||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities | 18,159 | 13,813 | 8,886 | |||
| Employee-related liabilities | 12,503 | 8,588 | 6,736 | |||
| Accounts payable | 5,656 | 5,225 | 2,150 | |||
| Debt | 1,236 | |||||
| Other liabilities | 148 | 44 | 45 | |||
| Other undisclosed current liabilities | 28,782 | 10,535 | 3,865 | |||
| Total current liabilities: | 47,089 | 24,392 | 14,032 | |||
| Noncurrent Liabilities | ||||||
| Long-term debt and lease obligation: | 1,949 | 2,423 | 3,819 | |||
| Operating lease, liability | 1,949 | 2,423 | 3,819 | |||
| Total noncurrent liabilities: | 3,898 | 4,846 | 3,819 | |||
| Total liabilities: | 50,987 | 29,238 | 17,851 | |||
| Equity | ||||||
| Equity, attributable to parent | 954,425 | 1,109,898 | 404,351 | |||
| Common stock | 5 | 5 | 4 | |||
| Additional paid in capital | 1,472,421 | 1,389,860 | 526,960 | |||
| Accumulated other comprehensive income (loss) | (1,274) | 209 | 271 | |||
| Accumulated deficit | (516,727) | (280,176) | (122,884) | |||
| Total equity: | 954,425 | 1,109,898 | 404,351 | |||
| Other undisclosed liabilities and equity | (1,949) | (2,423) | ||||
| TOTAL LIABILITIES AND EQUITY: | 1,003,463 | 1,136,713 | 422,202 | |||
Income Statement (P&L) ($ in thousands)
| 6/30/2022 TTM | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|
| Revenues | 30,829 | 25,000 | 5,593 | ||
| Other operating income | 1,449 | 4,544 | 5,593 | ||
| Gross profit: | 30,829 | 25,000 | 5,593 | ||
| Operating expenses | (268,829) | (186,836) | (77,724) | ||
| Other undisclosed operating loss | (5,593) | ||||
| Operating loss: | (238,000) | (161,836) | (77,724) | ||
| Loss from continuing operations: | (238,000) | (161,836) | (77,724) | ||
| Loss before gain (loss) on sale of properties: | ✕ | (238,000) | (161,836) | (77,724) | |
| Net loss: | (238,000) | (161,836) | (77,724) | ||
| Other undisclosed net income attributable to parent | 1,449 | 4,544 | 5,593 | ||
| Net loss available to common stockholders, diluted: | (236,551) | (157,292) | (72,131) | ||
Comprehensive Income ($ in thousands)
| 6/30/2022 TTM | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|
| Net loss: | (238,000) | (161,836) | (77,724) | ||
| Other comprehensive income (loss) | (1,483) | (62) | 271 | ||
| Comprehensive loss: | (239,483) | (161,898) | (77,453) | ||
| Other undisclosed comprehensive income, net of tax, attributable to parent | 1,449 | 4,544 | 5,593 | ||
| Comprehensive loss, net of tax, attributable to parent: | (238,034) | (157,354) | (71,860) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.